| 1 |
Kahnert K, Jörres RA, Behr J, et al. The diagnosis and treatment of COPD and its comorbidities[J]. Dtsch Arztebl Int, 2023, 120(25): 434-444.
|
| 2 |
Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease[J]. Lancet, 2022, 399(10342): 2227-2242.
|
| 3 |
李正欢，张晓云，陈 杨，等. 2020年慢性阻塞性肺疾病全球倡议《COPD诊断、治疗与预防全球策略》指南解读(一) ——稳定期药物管理[J]. 中国全科医学，2021, 24(8): 923-929.
|
| 4 |
黄浠婷，骆晓琳，王 净，等. 慢性阻塞性肺疾病患者吸入用药管理的证据总结[J]. 中国护理管理，2023, 23(11): 1720-1726.
|
| 5 |
Kume H. Role of airway smooth muscle in inflammation related to asthma and COPD[J]. Adv Exp Med Biol, 2021, 1303: 139-172.
|
| 6 |
Camoretti-Mercado B, Lockey RF. Airway smooth muscle pathophysiology in asthma[J]. J Allergy Clin Immunol, 2021, 147(6): 1983-1995.
|
| 7 |
Chetty A, Nielsen HC. Targeting airway smooth muscle hypertrophy in asthma: An approach whose time has come[J]. J Asthma Allergy, 2021, 14: 539-556.
|
| 8 |
Savin IA, Zenkova MA, Sen′kova AV. Bronchial asthma, airway remodeling and lung fibrosis as successive steps of one process[J]. Int J Mol Sci, 2023, 24(22): 10642.
|
| 9 |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志，2021, 44(3): 170-205.
|
| 10 |
唐楚娟，李 静，邓玎玎，等. 慢性阻塞性肺疾病患者吸入性糖皮质激素使用现状及指南依从性[J]. 中国医师杂志，2022, 24(7): 970-975.
|
| 11 |
慢性阻塞性肺疾病糖皮质激素规范管理撰写组. 慢性阻塞性肺疾病糖皮质激素规范管理专家共识(2021版)[J]. 中华结核和呼吸杂志，2021, 44(12): 1054-1063.
|
| 12 |
Heo YA. Budesonide/Glycopyrronium/Formoterol: A Review in COPD[J]. Drugs, 2021, 81(12): 1411-1422.
|
| 13 |
Li L, Zhao N, Ma X, et al. Personalized variable vs？fixed-dose systemic corticosteroid therapy in hospitalized patients with acute exacerbations of COPD: A prospective, multicenter, randomized, open-label clinical trial[J]. Chest, 2021, 160(5): 1660-1669.
|
| 14 |
Yang M, Li Y, Jiang Y, et al.Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis[J]. Eur Respir J, 2023, 61(2): 2200302.
|
| 15 |
Wechsler ME, Munitz A, Ackerman SJ, et al. Eosinophils in health and disease: A state-of-the-art review[J]. Mayo Clin Proc, 2021, 96(10): 2694-2707.
|
| 16 |
Ruiying W, Zhaoyun, Jianying X. Clinical features and three-year prognosis of AECOPD patients with different levels of blood eosinophils[J]. Heart Lung, 2022, 56: 29-39.
|
| 17 |
Muro S, Sugiura H, Darken P, et al. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts[J]. Respir Res, 2021, 22(1): 187.
|
| 18 |
Terry PD, Dhand R. Correction to: Inhalation Therapy for Stable COPD: 20 Years of GOLD Reports[J]. Adv Ther, 2021, 38(9): 4986-4988.
|
| 19 |
Venkatesan P. GOLD COPD report: 2024 update[J]. Lancet Respir Med, 2024, 12(1): 15-16.
|
| 20 |
王法霞，赖克方，陈如冲，等. 哮喘患者吸入表面激素减量后哮喘症状变化与诱导痰嗜酸性粒细胞比例的关系[J/CD]. 中华肺部疾病杂志(电子版), 2014, 7(5): 490-493.
|
| 21 |
张彩云，韩志海，孟激光，等. 稳定期COPD患者呼出气一氧化氮与外周血嗜酸性粒细胞水平的相关性分析[J]. 解放军医学院学报，2022, 43(4): 377-382, 389.
|
| 22 |
Bertolini F, Sprio AE, Baroso A, et al. Predictors of low and high exhaled nitric oxide values in asthma: a real-world study[J]. Respiration, 2022, 101(8): 746-756.
|
| 23 |
Sadr S, Tahermohammadi H, Kaveh S, et al. Fractional Exhalation nitric oxide (FeNO) changes in cystic fibrosis patients induced by compound honey syrup: a pretest-posttest clinical trial[J]. BMC Pulm Med, 2023, 23(1): 488.
|
| 24 |
Malli F, Gouvani A, Dimeas I, et al. Exhaled nitric oxide (FeNO) in patients hospitalized for an exacerbation of bronchiectasis and/or COPD : FeNO levels in COPD and bronchiectasis[J]. Adv Exp Med Biol, 2021, 1337: 323-330.
|
| 25 |
Xu X, Zhou L, Tong Z. The relationship of fractional exhaled nitric oxide in patients with AECOPD[J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 3037-3046.
|